Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Nov;175(11):1761-70.
doi: 10.1001/jamainternmed.2015.5214.

Shared Decision Making for Antidepressants in Primary Care: A Cluster Randomized Trial

Annie LeBlanc  1 , Jeph Herrin  2 , Mark D Williams  3 , Jonathan W Inselman  4 , Megan E Branda  4 , Nilay D Shah  5 , Emma M Heim  6 , Sara R Dick  6 , Mark Linzer  7 , Deborah H Boehm  7 , Kristen M Dall-Winther  8 , Marc R Matthews  9 , Kathleen J Yost  10 , Kathryn K Shepel  11 , Victor M Montori  12
Affiliations
Randomized Controlled Trial

Shared Decision Making for Antidepressants in Primary Care: A Cluster Randomized Trial

Annie LeBlanc et al. JAMA Intern Med. 2015 Nov.

Abstract

Importance: For antidepressants, the translation of evidence of comparative effectiveness into practice is suboptimal. This deficit directly affects outcomes and quality of care for patients with depression. To overcome this problem, we developed the Depression Medication Choice (DMC) encounter decision aid, designed to help patients and clinicians consider the available antidepressants and the extent to which they improved depression and other issues important to patients.

Objective: Estimate the effect of DMC on quality of the decision-making process and depression outcomes.

Design, setting, and participants: We conducted a cluster randomized trial of adults with moderate to severe depression considering treatment with an antidepressant. Primary care practices in 10 rural, suburban, and urban primary care practices across Minnesota and Wisconsin were randomly allocated to treatment of depression with or without use of the DMC decision aid.

Intervention: Depression Medication Choice, a series of cards, each highlighting the effect of the available options on an issue of importance to patients for use during face-to-face consultations.

Main outcomes and measures: Decision-making quality as judged by patient knowledge and involvement in decision making, patient and clinician decisional comfort (Decisional Conflict Scale) and satisfaction, encounter duration, medication adherence, depression symptoms, and the Patient Health Questionnaire for depression (PHQ-9).

Results: We enrolled 117 clinicians and 301 patients (67% women; mean [SD] age, 44 [15] years; mean [SD] PHQ-9 score, 15 [4]) into the trial. Compared with usual care (UC), use of DMC significantly improved patients' decisional comfort (DMC, 80% vs UC, 75%; P = .02), knowledge (DMC, 65% vs UC, 56%; P = .03), satisfaction (risk ratio [RR], from 1.25 [P = .81] to RR, 2.4 [P = .002] depending on satisfaction domain), and involvement (DMC, 47% vs UC, 33%; P<.001). It also improved clinicians' decisional comfort (DMC, 80% vs UC, 68%; P < .001) and satisfaction (RR, 1.64; P = .02). There were no differences in encounter duration, medication adherence, or improvement of depression control between arms.

Conclusions and relevance: The DMC decision aid helped primary care clinicians and patients with moderate to severe depression select antidepressants together, improving the decision-making process without extending the visit. On the other hand, DMC had no discernible effect on medication adherence or depression outcomes. By translating comparative effectiveness into patient-centered care, use of DMC improved the quality of primary care for patients with depression.

Trial registration: clinicaltrials.gov Identifier: NCT01502891.

PubMed Disclaimer

Figures

Figure 1
Figure 1
This decision aid presents itself in form of 4”x10” laminated cards The Depression Medication Choice Encounter Decision Aid
Figure 2
Figure 2
Flow of Participants
See this image and copyright information in PMC

Comment in

References

    1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617–627. - PMC - PubMed
    1. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851–858. - PubMed
    1. Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007;27(8):959–985. - PMC - PubMed
    1. Merikangas KR, Ames M, Cui L, et al. The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007;64(10):1180–1188. - PMC - PubMed
    1. Simon GE. Long-term prognosis of depression in primary care. Bull World Health Organ. 2000;78(4):439–445. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data